null

Anti-TriMethyl-Histone H3-K27 Antibody (CAB2363)

SKU:
CAB2363
Product Type:
Antibody
Applications:
WB
IHC
IF
IP
ChIP
Reactivity:
Human
Mouse
Rat
Host Species:
Rabbit
Isotype:
IgG
Research Area:
Epigenetics and Nuclear Signaling
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-TriMethyl-Histone H3-K27 Antibody CAB2363
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-TriMethyl-Histone H3-K27 Antibody CAB2363
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-TriMethyl-Histone H3-K27 Antibody CAB2363
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-TriMethyl-Histone H3-K27 Antibody CAB2363
  • Epigenetics and Nuclear Signaling Antibodies 3 Anti-TriMethyl-Histone H3-K27 Antibody CAB2363
$167 - $503
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

Anti-TriMethyl-Histone H3-K27 Antibody (CAB2363)

The Trimethyl-Histone H3 (K27) Polyclonal Antibody (CAB2363) is a key tool for researchers studying epigenetic modifications in gene expression. This antibody, raised in rabbits, specifically targets the trimethylated form of histone H3 at lysine 27, a crucial histone modification involved in gene regulation and chromatin remodeling. Histone modifications, such as trimethylation of histone H3 at lysine 27, play a critical role in controlling gene expression and cellular functions. The CAB2363 antibody is highly reactive with human samples and has been validated for use in various applications, including Western blot and immunohistochemistry.

It enables researchers to detect and analyze the presence of trimethylated histone H3 (K27) in different cell types, providing valuable insights into the epigenetic regulation of gene expression.Research into histone modifications like trimethylation of histone H3 at lysine 27 is essential for understanding how changes in chromatin structure can impact gene expression and contribute to various diseases, including cancer and developmental disorders. By studying the role of this specific histone modification, researchers can uncover potential therapeutic targets for intervention in epigenetic-related diseases.